Otofarma S.P.A.

Otofarma S.P.A.'s next confirmed earnings release is scheduled for March 3, 2027.

As of December 31, 2024, Otofarma S.P.A. has 5.76M shares outstanding.

As of December 31, 2024, Otofarma S.P.A. maintains a current ratio of 2.11, meaning it holds 2.1x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended December 31, 2024, Otofarma S.P.A. posted a return on equity (ROE) of 16.70, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 12.03 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 7.59, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 10.56, useful for judging operating efficiency across full business cycles. Inventory turnover of 9.78 indicates how many times Otofarma S.P.A. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended December 31, 2024, Otofarma S.P.A. recorded 986,000.00 in income tax expense. That works out to an effective tax rate of 58.66, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 1.68M, leaving 698,000.00 in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Otofarma S.P.A.'s stock has declined approximately 61.82% over the past 52 weeks. The 50-day moving average sits at 2.40, while the 200-day moving average is 3.45.

Over the twelve months ended December 31, 2024, Otofarma S.P.A. generated 15.20M in revenue and converted that into 698,000.00 in net income, yielding earnings per share of 0.12. EBITDA reached 2.31M, while operating income came in at 1.94M.

As of December 31, 2024, Otofarma S.P.A. holds 2.52M in cash and equivalents against 2.88M in total debt, resulting in a net debt position of 368,000.00. Total book value stands at 5.09M, with working capital of 3.68M providing operational flexibility.

Otofarma S.P.A. produced 2.93M in operating cash flow over the twelve months ended December 31, 2024.

Over the twelve months ended December 31, 2024, Otofarma S.P.A. posted a gross margin of 88.55, reflecting its pricing power and cost economics. The operating margin of 12.73 and net profit margin of 4.59 provide insight into operational efficiency.